-
1
-
-
67650874081
-
Cancer statistics, 2009
-
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
-
(2009)
CA Cancer J Clin
, vol.59
, pp. 225-249
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Hao, Y.4
Xu, J.5
Thun, M.J.6
-
2
-
-
0002241917
-
Metastatic brain tumors
-
Kaye AH, Laws ER, editors Philadelphia, PA: Churchill Livingstone
-
Sawaya R, Bindal RK, Lang FF, Abi-Said D. Metastatic brain tumors. In: Kaye AH, Laws ER, editors. Brain tumors. Philadelphia, PA: Churchill Livingstone; 2001. pp. 999-1026.
-
(2001)
Brain Tumors
, pp. 999-1026
-
-
Sawaya, R.1
Bindal, R.K.2
Lang, F.F.3
Abi-Said, D.4
-
3
-
-
0003007979
-
Cutaneous melanoma
-
DeVita VT, Hellman S, Rosenberg SA, editors Philadelphia, PA: Lippincott Williams & Wilkins
-
Lotze MT, Dallal RM, Kirkwood JM, Flickinger JC. Cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. pp. 2012-2069.
-
(2001)
Cancer: Principles and Practice of Oncology
, pp. 2012-2069
-
-
Lotze, M.T.1
Dallal, R.M.2
Kirkwood, J.M.3
Flickinger, J.C.4
-
4
-
-
2142644507
-
Determinants of outcome in melanoma patients with cerebral metastases
-
Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22:1293-1300.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1293-1300
-
-
Fife, K.M.1
Colman, M.H.2
Stevens, G.N.3
Firth, I.C.4
Moon, D.5
Shannon, K.F.6
-
5
-
-
79953781233
-
Prognostic factors for survival in melanoma patients with brain metastases
-
Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011; 117:1687-1696.
-
(2011)
Cancer
, vol.117
, pp. 1687-1696
-
-
Davies, M.A.1
Liu, P.2
McIntyre, S.3
Kim, K.B.4
Papadopoulos, N.5
Hwu, W.J.6
-
6
-
-
0030094932
-
Cranial irradiation after surgical excision of brain metastases in melanoma patients
-
Skibber JM, Soong SJ, Austin L, Balch CM, Sawaya RE. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 1996; 3:118-123.
-
(1996)
Ann Surg Oncol
, vol.3
, pp. 118-123
-
-
Skibber, J.M.1
Soong, S.J.2
Austin, L.3
Balch, C.M.4
Sawaya, R.E.5
-
7
-
-
44849122610
-
Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features
-
Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 2008; 10:199-207.
-
(2008)
Neuro Oncol
, vol.10
, pp. 199-207
-
-
Raizer, J.J.1
Hwu, W.J.2
Panageas, K.S.3
Wilton, A.4
Baldwin, D.E.5
Bailey, E.6
-
8
-
-
0027947444
-
Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma
-
Buzaid A, Legha SS, Balch CM, Ross M, Ring S, Plager C, et al. Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma. Cancer 1994; 74:2476-2482.
-
(1994)
Cancer
, vol.74
, pp. 2476-2482
-
-
Buzaid, A.1
Legha, S.S.2
Balch, C.M.3
Ross, M.4
Ring, S.5
Plager, C.6
-
9
-
-
0032428422
-
Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases
-
Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 1998; 8:549-556.
-
(1998)
Melanoma Res
, vol.8
, pp. 549-556
-
-
Buzaid, A.C.1
Colome, M.2
Bedikian, A.3
Eton, O.4
Legha, S.S.5
Papadopoulos, N.6
-
10
-
-
0037089629
-
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial
-
Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20:2045-2052.
-
(2002)
J Clin Oncol
, vol.20
, pp. 2045-2052
-
-
Eton, O.1
Legha, S.S.2
Bedikian, A.Y.3
Lee, J.J.4
Buzaid, A.C.5
Hodges, C.6
-
11
-
-
59549100740
-
A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-a-2b (IFN) in patients (pts) with high risk for melanoma recurrence
-
Kim KB, Legha SS, Gonzalez R, Anderson C, Papadopoulos NE, Eton O, et al. A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-a-2b (IFN) in patients (pts) with high risk for melanoma recurrence. Melanoma Res 2009; 19:42-49.
-
(2009)
Melanoma Res
, vol.19
, pp. 42-49
-
-
Kim, K.B.1
Legha, S.S.2
Gonzalez, R.3
Anderson, C.4
Papadopoulos, N.E.5
Eton, O.6
-
12
-
-
3242798965
-
Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma
-
Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer 2004; 101:596-603.
-
(2004)
Cancer
, vol.101
, pp. 596-603
-
-
Kim, K.B.1
Eton, O.2
East, M.J.3
Hodges, C.4
Papadopoulos, N.E.5
Grimm, E.A.6
Bedikian, A.Y.7
-
13
-
-
0013613001
-
A phase-II study of biochemotherapy using interleukin-2 (IL-2) + interferon alpha-2A (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in patients with metastatic melanoma [abstract 1179]
-
Legha S, Plager C, Ring S. A phase-II study of biochemotherapy using interleukin-2 (IL-2) + interferon alpha-2A (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in patients with metastatic melanoma [abstract 1179]. Proc Am Soc Clin Oncol 1992; 11:343.
-
(1992)
Proc Am Soc Clin Oncol
, vol.11
, pp. 343
-
-
Legha, S.1
Plager, C.2
Ring, S.3
-
14
-
-
0029906912
-
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha
-
Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996; 7:827-835.
-
(1996)
Ann Oncol
, vol.7
, pp. 827-835
-
-
Legha, S.S.1
Ring, S.2
Bedikian, A.3
Plager, C.4
Eton, O.5
Buzaid, A.C.6
-
15
-
-
0031805726
-
Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
-
Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16:1752-1759.
-
(1998)
J Clin Oncol
, vol.16
, pp. 1752-1759
-
-
Legha, S.S.1
Ring, S.2
Eton, O.3
Bedikian, A.4
Buzaid, A.C.5
Plager, C.6
Papadopoulos, N.7
-
16
-
-
0024448792
-
A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma
-
Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989; 64:2024-2029.
-
(1989)
Cancer
, vol.64
, pp. 2024-2029
-
-
Legha, S.S.1
Ring, S.2
Papadopoulos, N.3
Plager, C.4
Chawla, S.5
Benjamin, R.6
-
17
-
-
70350662205
-
Phase II study of CTD (cisplatin, paclitaxel, DTIC) in metastatic melanoma (MM)
-
Papadopoulos NE, Bedikian AY, Ring S, Kim KB, Camacho L, Eton O. Phase II study of CTD (cisplatin, paclitaxel, DTIC) in metastatic melanoma (MM). Am J Clin Oncol 2009; 32:509-514.
-
(2009)
Am J Clin Oncol
, vol.32
, pp. 509-514
-
-
Papadopoulos, N.E.1
Bedikian, A.Y.2
Ring, S.3
Kim, K.B.4
Camacho, L.5
Eton, O.6
-
18
-
-
84891923747
-
Phase II study of 'hybrid' biochemotherapy for advanced melanoma [abstract 18007]
-
Papadopoulos NE, Eton O, Kim KB, Camacho LH, Hwu P, Bedikian AY. Phase II study of 'hybrid' biochemotherapy for advanced melanoma [abstract 18007]. J Clin Oncol 2006; 24:686s.
-
(2006)
J Clin Oncol
, vol.24
-
-
Papadopoulos, N.E.1
Eton, O.2
Kim, K.B.3
Camacho, L.H.4
Hwu, P.5
Bedikian, A.Y.6
-
19
-
-
84891908443
-
Long-term clinical results of the combination of cisplatin (C), vinblastine (V), DTIC (D) and interferon-alfa (I) with or without tamoxifen (T) for metastatic melanoma [abstract 8039]
-
Sanguino AM, Bedikian AY, Legha SS, Detry MA, Papadopoulos NE, Hwu P, et al. Long-term clinical results of the combination of cisplatin (C), vinblastine (V), DTIC (D) and interferon-alfa (I) with or without tamoxifen (T) for metastatic melanoma [abstract 8039]. J Clin Oncol 2006; 24:462s.
-
(2006)
J Clin Oncol
, vol.24
-
-
Sanguino, A.M.1
Bedikian, A.Y.2
Legha, S.S.3
Detry, M.A.4
Papadopoulos, N.E.5
Hwu, P.6
-
20
-
-
33845382806
-
Nonparametric estimation from incomplete observations
-
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
-
(1958)
J Am Stat Assoc
, vol.53
, pp. 457-481
-
-
Kaplan, E.L.1
Meier, P.2
-
21
-
-
0000120995
-
A class of K-sample tests for comparing the cumulative incidence of a competing risk
-
Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141-1154.
-
(1988)
Ann Stat
, vol.16
, pp. 1141-1154
-
-
Gray, R.J.1
-
22
-
-
0037197627
-
Non-parametric confidence interval estimation for competing risks analysis: Application to contraceptive data
-
Choudhury JB. Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 2002; 21:1129-1144.
-
(2002)
Stat Med
, vol.21
, pp. 1129-1144
-
-
Choudhury, J.B.1
-
23
-
-
1542532754
-
A proportional hazards model for the subdistribution of a competing risk
-
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94:496-509.
-
(1999)
J Am Stat Assoc
, vol.94
, pp. 496-509
-
-
Fine, J.P.1
Gray, R.J.2
-
24
-
-
0029130766
-
Role of computed tomography in the staging of patients with local-regional metastases of melanoma
-
Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995; 13:2104-2108.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2104-2108
-
-
Buzaid, A.C.1
Tinoco, L.2
Ross, M.I.3
Legha, S.S.4
Benjamin, R.S.5
-
25
-
-
79952987663
-
Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck
-
Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, et al. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res 2011; 21:127-130.
-
(2011)
Melanoma Res
, vol.21
, pp. 127-130
-
-
Alvarado, G.C.1
Papadopoulos, N.E.2
Hwu, W.J.3
Bedikian, A.Y.4
Homsi, J.5
Myers, J.N.6
-
26
-
-
78951487923
-
NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic syndromes
-
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 2011; 9:30-56.
-
(2011)
J Natl Compr Canc Netw
, vol.9
, pp. 30-56
-
-
Greenberg, P.L.1
Attar, E.2
Bennett, J.M.3
Bloomfield, C.D.4
De Castro, C.M.5
Deeg, H.J.6
-
27
-
-
0035940041
-
Treatment of brain metastases of malignant melanoma with temozolomide
-
Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med 2001; 345:621-622.
-
(2001)
N Engl J Med
, vol.345
, pp. 621-622
-
-
Biasco, G.1
Pantaleo, M.A.2
Casadei, S.3
-
30
-
-
84891953873
-
BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients with BRAF V600E/K mutation-positive melanoma with brain metastases (mets) [abstract 8501]
-
Kirkwood JM, Long GV, Trefzer U, Davies MA, Ascierto PA, Chapman PB, et al. BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients with BRAF V600E/K mutation-positive melanoma with brain metastases (mets) [abstract 8501]. J Clin Oncol 2012; 30:2012.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2012
-
-
Kirkwood, J.M.1
Long, G.V.2
Trefzer, U.3
Davies, M.A.4
Ascierto, P.A.5
Chapman, P.B.6
-
31
-
-
84865072027
-
The NIBIT-MI trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases [abstract]
-
Maio M, Testori A, Ascierto PA, et al. The NIBIT-MI trial: activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases [abstract]. J Clin Oncol 2012; 30:8529.
-
(2012)
J Clin Oncol
, vol.30
, pp. 8529
-
-
Maio, M.1
Testori, A.2
Ascierto, P.A.3
-
32
-
-
77957587190
-
Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases [abstract 8523]
-
Lawrence DP, Hamid O, McDermott DF, et al. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases [abstract 8523]. J Clin Oncol 2010; 28:15s.
-
(2010)
J Clin Oncol
, vol.28
-
-
Lawrence, D.P.1
Hamid, O.2
McDermott, D.F.3
|